Effect of Interleukin-17 in the Activation of Monocyte Subsets in Patients with ST-Segment Elevation Myocardial Infarction

Figure 3

Expression of surface markers on monocytes stimulated with IL-17. Human CD14⁺⁺CD16⁻ and CD14⁺⁺CD16⁺/CD14⁺CD16⁺⁺ monocytes were treated with IL-17, IFN-γ, which was used as a positive control, IL-17/IFN-γ, or culture medium alone, which was used as a negative control, for 24 hours. Human CD14⁺⁺CD16⁻ in STEMI: (a) TLR4, (e) CD86, and (i) HLA-DR. Human CD14⁺⁺CD16⁻in post-STEMI: (b) TLR4, (f) CD86, and (j) HLA-DR. Human CD14⁺⁺CD16⁺/CD14⁺CD16⁺⁺ monocytes in STEMI: (c) TLR4, (g) CD86, and (k) HLA-DR. CD14⁺⁺CD16⁺/CD14⁺CD16⁺⁺ monocytes post-STEMI: (d) TLR4, (h) CD86, and (l) HLA-DR. Expression levels of TLR4, CD86, and HLA-DR are expressed as MFI. White column: STEMI; black column: post-STEMI; . .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)